Results 141 to 150 of about 3,811,568 (245)

Sarcopenia Is Associated With Severe Treatment Toxicity and Mortality in Older Adults With Advanced Cancer: A Secondary Analysis

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 5, October 2026.
ABSTRACT Background Sarcopenia, a loss of muscle strength, quantity and performance that occurs primarily from ageing or secondary to disease, is hypothesized to worsen treatment outcomes in patients with cancer. Most published studies, however, focus solely on muscle quantity in patients under 70.
Lindsey J. Mattick, Mostafa Mohammed, Chin‐Shang Li, Rachael G. Tylock, Kah Poh Loh, Marie A. Flannery, Luke J. Peppone, Po‐Ju Lin, Marcus D. Goncalves, Bette J. Caan, Elizabeth M. Cespedes Feliciano, Karteek Popuri, Mirza Faisal Beg, James D. Bearden, Jeffrey Berenberg, Khalil Katato, Karen M. Mustian, Supriya G. Mohile, Richard F. Dunne   +18 more
wiley   +1 more source

Longitudinally Monitoring Prostate Cancer Bone Metastasis and Treatment Response via Circulating Extracellular Vesicles

Journal of Extracellular Vesicles, Volume 15, Issue 10, October 2026.
ABSTRACT Lethal prostate cancer (PCa) is dominated by treatment‐refractory progression in bone. In this study, we used plasma‐derived extracellular vesicles (EVs) for monitoring the tumour and therapy‐induced changes in the bone tumour microenvironment (bone‐TME) in men with bone metastatic PCa (M1b PCa).
Emanuela Gentile, Paul G. Corn, Martha Zavridou, James P. Long, Jian H. Song, Anh Hoang, Andrew W. Hahn, Eleonora Dondossola, William Norton, Sue‐Hwa Lin, Christopher J. Logothetis, Theocharis Panaretakis   +11 more
wiley   +1 more source

Cuprous oxide nanoparticles inhibit prostate cancer by attenuating the stemness of cancer cells via inhibition of the Wnt signaling pathway

International Journal of Nanomedicine, 2017
Ye Wang,1,* Qi-Wei Yang,1,2,* Qing Yang,2,* Tie Zhou,1 Min-Feng Shi,1,3 Chen-Xia Sun,4 Xiu-Xia Gao,4 Yan-Qiong Cheng,1 Xin-Gang Cui,2 Ying-Hao Sun1 1Department of Urology, Changhai Hospital, 2Department of Urology, The Third Affiliated Hospital ...
Wang Y, Yang QW, Yang Q, Zhou T, Shi MF, Sun CX, Gao XX, Cheng YQ, Cui XG, Sun YH   +9 more
doaj  

Cancer Cell Metastasis: From Molecular Mechanisms to Therapeutic Strategies

MedComm, Volume 7, Issue 10, October 2026.
The schematic representation of intrinsic and extrinsic influences of cancer cell metastasis. Genomic evolution of metastatic tumor cells (MTCs) promotes their metastatic phenotypes and reconstruct the primary tumor microenvironment. During MTCs migration along different routes (blood circulation, lymphatic vessels, and perineuronal spaces), the ...
Yupeng Zhao, Wenchao Xu, Yibo Wang, Haoran Huang, Yu Su, Li Zhou, Jianzhou Liu, Junchao Guo   +7 more
wiley   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancer

The Prostate, Volume 86, Issue 14, Page 1461-1469, October 2026.
ABSTRACT Background Upfront treatment intensification with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor has become a standard approach for metastatic hormone‐sensitive prostate cancer (mHSPC). However, prognosis remains poor for some patients despite second‐generation androgen receptor antagonist‐based doublet therapy.
Saizo Fujimoto, Tsuyoshi Morita, Yutaka Yamamoto, Teruo Inamoto, Keita Tamura, Yuki Yoshikawa, Ryoichi Maenosono, Akihito Takeuchi, Kiyoshi Takahara, Seitetsu Sugiyama, Kazumasa Komura, Takafumi Yanagisawa, Wataru Fukuokaya, Takahiro Kimura, Kazutoshi Fujita   +14 more
wiley   +1 more source

The role of macrophage migration inhibitory factor (MIF) in the pathogenesis and progression of cardiovascular disease

British Journal of Pharmacology, Volume 183, Issue 19, Page 5732-5751, October 2026.
Abstract Cardiovascular disease (CVD) remains the leading global cause of death, driven by complex mechanisms, in which chronic inflammation plays a central role. Inflammatory pathways contribute to all stages of CVD, from endothelial dysfunction and plaque formation to erosion, rupture and myocardial injury.
Shreya Mahabhashyam, James Harris, Jürgen Bernhagen, Antony Vinh, Katrina M. Mirabito Colafella   +4 more
wiley   +1 more source

NRF2/xCT‐Mediated Antioxidant Adaptation Attenuates Apoptosis Induced by ASCT2 Inhibition in Prostate Cancer

Cancer Science, Volume 117, Issue 10, Page 2769-2789, October 2026.
ASCT2 inhibition induces ROS accumulation and activates NRF2‐dependent xCT upregulation in prostate cancer. This adaptive response partially supports residual cystine acquisition and glutathione synthesis, whereas combined ASCT2 and xCT inhibition disrupts redox compensation and predominantly promotes apoptotic cell death.
Jiaxing Wei, Yasutaka Yamada, Takaaki Tamura, Masahiro Sugiura, Xue Zhao, Meng Ni, Adilan Aierken, Tomokazu Sazuka, Yusuke Imamura, Shinichi Sakamoto   +9 more
wiley   +1 more source

Penile Metastasis From Castration-Resistant Prostate Cancer: A Case Report. [PDF]

IJU Case Rep
Asakura S, Nakagami Y, Inoue T, Matsui Y, Oshinomi K, Nagata M, Fukagai T, Ohira Y, Yamochi Y.   +8 more
europepmc   +1 more source

Erratum: [Corrigendum] Antitumour activity of TH1579, a novel MTH1 inhibitor, against castration-resistant prostate cancer. [PDF]

Oncol Lett
Hu M, Ning J, Mao L, Yu Y, Wu Y.
europepmc   +1 more source